Collaborative Commercialization at Gilead Sciences: Resolving the Innovation Vs. Access Tradeoff Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Collaborative Commercialization at Gilead Sciences: Resolving the Innovation Vs. Access Tradeoff case study

At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Collaborative Commercialization at Gilead Sciences: Resolving the Innovation Vs. Access Tradeoff case study is a Harvard Business School (HBR) case study written by Nita Sachan, Anand Tatambothla, Revati Nehru, Charles Dhanaraj. The Collaborative Commercialization at Gilead Sciences: Resolving the Innovation Vs. Access Tradeoff (referred as “Gilead Viread” from here on) case study provides evaluation & decision scenario in field of Innovation & Entrepreneurship. It also touches upon business topics such as - Value proposition, Health, Innovation, Joint ventures, Risk management.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment

---

Case Description of Collaborative Commercialization at Gilead Sciences: Resolving the Innovation Vs. Access Tradeoff Case Study

The case deals with Gilead Sciences, a bio-pharmaceutical company with several FDA approved HIV/AIDS drugs. In 2006, the company launched the Gilead Access Program to enhance access to HIV/AIDS drugs in developing countries. In India, which also happened to be the largest producer of generic drugs, Gilead signed a voluntary licensing agreement for its drug, Viread, with 13 companies. By 2011, Mylan (previously known as Matrix Laboratories), one of the 13 Indian companies, had emerged as the leading supplier for Viread, with two-thirds of the global market. In order to accelerate its market reach, Gilead wanted to expand the scope of the agreement with four major Indian companies, including Mylan. Gregg Alton, Executive Vice President for Corporate and Medical Affairs, had to decide how he would convince his partners to come on board and how to execute the agreement.

Case Authors : Nita Sachan, Anand Tatambothla, Revati Nehru, Charles Dhanaraj

Topic : Innovation & Entrepreneurship

Related Areas : Health, Innovation, Joint ventures, Risk management

---

Calculating Net Present Value (NPV) at 6% for Collaborative Commercialization at Gilead Sciences: Resolving the Innovation Vs. Access Tradeoff Case Study

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 6 %	Discounted Cash Flows
Year 0	(10002244)	-10002244	-	-
Year 1	3470819	-6531425	3470819	0.9434	3274358
Year 2	3957906	-2573519	7428725	0.89	3522522
Year 3	3938595	1365076	11367320	0.8396	3306920
Year 4	3232764	4597840	14600084	0.7921	2560652
TOTAL			14600084		12664452

The Net Present Value at 6% discount rate is 2662208

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting

What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.

---

Capital Budgeting Approaches

Methods of Capital Budgeting

There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Net Present Value
2. Internal Rate of Return
3. Profitability Index
4. Payback Period

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Gilead Viread shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.
2. Timing of the expected cash flows – stockholders of Gilead Viread have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.

---

Formula and Steps to Calculate Net Present Value (NPV) of Collaborative Commercialization at Gilead Sciences: Resolving the Innovation Vs. Access Tradeoff

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Innovation & Entrepreneurship Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Gilead Viread often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Gilead Viread needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 15 %	Discounted Cash Flows
Year 0	(10002244)	-10002244	-	-
Year 1	3470819	-6531425	3470819	0.8696	3018103
Year 2	3957906	-2573519	7428725	0.7561	2992746
Year 3	3938595	1365076	11367320	0.6575	2589690
Year 4	3232764	4597840	14600084	0.5718	1848343
TOTAL					10448882

The Net NPV after 4 years is 446638

(10448882 - 10002244 )

---

Calculating Net Present Value (NPV) at 20%

If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 20 %	Discounted Cash Flows
Year 0	(10002244)	-10002244	-	-
Year 1	3470819	-6531425	3470819	0.8333	2892349
Year 2	3957906	-2573519	7428725	0.6944	2748546
Year 3	3938595	1365076	11367320	0.5787	2279280
Year 4	3232764	4597840	14600084	0.4823	1559010
TOTAL					9479185

The Net NPV after 4 years is -523059

At 20% discount rate the NPV is negative (9479185 - 10002244 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Gilead Viread to discount cash flow at lower discount rates such as 15%.

Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Gilead Viread has a NPV value higher than Zero then finance managers at Gilead Viread can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Gilead Viread, then the stock price of the Gilead Viread should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Gilead Viread should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

Understanding of risks involved in the project.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

What can impact the cash flow of the project.

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

What will be a multi year spillover effect of various taxation regulations.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.

---

Negotiation Strategy of Collaborative Commercialization at Gilead Sciences: Resolving the Innovation Vs. Access Tradeoff

References & Further Readings

Nita Sachan, Anand Tatambothla, Revati Nehru, Charles Dhanaraj (2018), "Collaborative Commercialization at Gilead Sciences: Resolving the Innovation Vs. Access Tradeoff Harvard Business Review Case Study. Published by HBR Publications.